Mallinckrodt - Articles and news items

Mallinckrodt’s muscular dystrophy drug receives FDA fast track designation

Industry news / 26 August 2016 / Niamh Louise Marriott, Digital Content Producer

For the treatment of Duchenne muscular dystrophy (DMD), Synacthen Depot is a synthetic 24 amino acid melanocortin receptor agonist. Outside the US, it…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+